PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Free Report) CFO Kevin Waters sold 25,000 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $72.47, for a total transaction of $1,811,750.00. Following the transaction, the chief financial officer now directly owns 96,096 shares in the company, valued at $6,964,077.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Kevin Waters also recently made the following trade(s):
- On Monday, September 16th, Kevin Waters sold 25,000 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $82.51, for a total transaction of $2,062,750.00.
PROCEPT BioRobotics Stock Down 4.7 %
Shares of PRCT stock traded down $3.38 during trading on Thursday, reaching $69.08. The company’s stock had a trading volume of 551,832 shares, compared to its average volume of 599,168. The company has a debt-to-equity ratio of 0.20, a current ratio of 7.51 and a quick ratio of 6.49. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of -34.18 and a beta of 1.03. The stock’s 50-day moving average price is $75.18 and its 200 day moving average price is $66.04. PROCEPT BioRobotics Co. has a 1-year low of $24.83 and a 1-year high of $85.81.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on PRCT. Wells Fargo & Company boosted their price target on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Bank of America boosted their price target on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Piper Sandler reissued an “overweight” rating and issued a $75.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, October 8th. TD Cowen boosted their price target on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Finally, Truist Financial boosted their price target on shares of PROCEPT BioRobotics from $74.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, PROCEPT BioRobotics currently has a consensus rating of “Buy” and a consensus price target of $86.40.
Get Our Latest Stock Report on PRCT
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in PROCEPT BioRobotics by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 4,184,585 shares of the company’s stock worth $175,376,000 after acquiring an additional 109,694 shares in the last quarter. M&G Plc purchased a new stake in shares of PROCEPT BioRobotics during the 2nd quarter worth approximately $8,507,000. Federated Hermes Inc. lifted its position in shares of PROCEPT BioRobotics by 788.9% during the 2nd quarter. Federated Hermes Inc. now owns 183,420 shares of the company’s stock worth $11,205,000 after buying an additional 162,785 shares during the last quarter. Nicholas Investment Partners LP purchased a new stake in shares of PROCEPT BioRobotics during the 2nd quarter worth approximately $4,657,000. Finally, ProShare Advisors LLC lifted its position in shares of PROCEPT BioRobotics by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 7,250 shares of the company’s stock worth $358,000 after buying an additional 570 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.
PROCEPT BioRobotics Company Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
See Also
- Five stocks we like better than PROCEPT BioRobotics
- What Makes a Stock a Good Dividend Stock?
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Investing In Automotive Stocks
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- 5 discounted opportunities for dividend growth investors
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.